SCHEMBL19260615

SCHEMBL19260615

COc1cc2c(Cl)c3ccccc3nc2cc1OCC1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR9 Q9NR96 4/20 0.49
▸ TLR7 Q9NYK1 2/20 0.49
▸ EPHA2 P29317 5/20 0.48
▸ NSD2 O96028 2/20 0.47
▸ EPHB4 P54760 2/20 0.47
▸ ERBB2 P04626 1/20 0.47
▸ EHMT2 Q96KQ7 3/20 0.44
▸ DNMT3A Q9Y6K1 1/20 0.44
▸ PIK3CD O00329 2/20 0.43
▸ PIK3CA P42336 2/20 0.43
▸ PIK3CB P42338 2/20 0.43
▸ PIK3CG P48736 2/20 0.43
▸ KDM1A O60341 1/20 0.43
▸ RCOR1 Q9UKL0 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ RBP4 P02753 1/20 0.42
▸ ALOX5AP P20292 1/20 0.42
▸ FEN1 P39748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260528 0.88 TLR9 (0.48) TLR9TLR7EPHA2NSD2EPHB4
SCHEMBL3132645 0.81 EPHA2 (0.55) EPHA2NSD2EPHB4ERBB2PIK3CD
SCHEMBL20952048 0.80 NSD2 (0.52) TLR9TLR7EPHA2NSD2EPHB4
SCHEMBL664787 0.77 EPHA2 (0.52) EPHA2NSD2EPHB4ERBB2PIK3CD
SCHEMBL17179600 0.77 EPHA2 (0.52) EPHA2NSD2EPHB4ERBB2PIK3CD
SCHEMBL2459163 0.77 HTR6 (0.54) BCHERBP4ALOX5APFEN1
SCHEMBL4499579 0.77 RBP4 (0.53) BCHERBP4ALOX5APFEN1
SCHEMBL5935711 0.76 CSF1R (0.52) RBP4
SCHEMBL5016778 0.76 NSD2 (0.49) TLR9TLR7EPHA2NSD2EPHB4
SCHEMBL18788125 0.74 DNMT1 (0.57) EHMT2DNMT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 — — EP disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 — — US disclosed
EP-3416963-A1 HISTONE METHYLTRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2018-12-26 — — EP disclosed
WO-2017142947-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 TLR9 3384/4885TLR7 4549/4885EPHA2 4690/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 TLR9 3384/4885TLR7 4549/4885EPHA2 4690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback